Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23512484 | 0.93 | MAPT (0.50) | MAPTKDM4ECYP3A4LOXL2LMNA | |
| SCHEMBL2504209 | 0.88 | KDM4E (0.68) | MAPTKDM4ECYP3A4LOXL2NCF1 | |
| N-Benzylmethylamine SCHEMBL28672539 | 0.87 | CYP3A4 (0.77) | MAPTKDM4ECYP3A4LOXL2LMNA | |
| Hydrochloric Acid SCHEMBL30925271 | 0.85 | KDM4E (0.74) | MAPTKDM4ECYP3A4LOXL2NCF1 | |
| SCHEMBL4396092 | 0.80 | LMNA (0.77) | MAPTLMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL13184538 | 0.80 | KDM4E (0.59) | MAPTKDM4ECYP3A4LOXL2ALDH1A1 | |
| Dimethylamine SCHEMBL8528675 | 0.79 | TP53 (0.53) | MAPTLMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL13407790 | 0.79 | KDM4E (0.52) | MAPTKDM4ECYP3A4LOXL2NCF1 | |
| SCHEMBL13186206 | 0.79 | L3MBTL1 (0.56) | MAPTKDM4ELMNAALDH1A1L3MBTL1 | |
| SCHEMBL36295 | 0.78 | TP53 (0.67) | LMNAALDH1A1L3MBTL1MAPK1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024359-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | claimed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| CN-117362304-A | Carboxamide substituted hetero tricyclic derivative, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023150630-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4169944-A1 | PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023012263-A1 | SOLID ORAL PEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2023-02-09 | — | — | WO | disclosed |
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | NOVO NORDISK AS (DK) | 2023-01-05 | — | — | US | disclosed |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7235543-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117154-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2007-05-24 | — | — | US | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | MAPT 2686/4885KDM4E 2780/4885CYP3A4 292/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885KDM4E 1618/4885CYP3A4 537/4885 |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | MAPT 802/4885KDM4E 1876/4885CYP3A4 1404/4885 |
| US-20230000949-A1 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | PCSK9, EGFR, PCSK6 | MAPT 539/4885KDM4E 2095/4885CYP3A4 4747/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885KDM4E 1618/4885CYP3A4 537/4885 |
| US-20070117154-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | F2, BCAT1, DAO | MAPT 3743/4885KDM4E 411/4885CYP3A4 250/4885 |
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | MAPT 412/4885KDM4E 2936/4885CYP3A4 3539/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | MAPT 4037/4885KDM4E 4689/4885CYP3A4 1903/4885 |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, BRD1 | MAPT 1823/4885KDM4E 4293/4885CYP3A4 2376/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | MAPT 2027/4885KDM4E 1895/4885CYP3A4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.